Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  January 11, 2022
(Exact name of registrant as specified in its charter)
Delaware 0-26642 87-0494517
(State or other jurisdiction of
File Number)
 (IRS Employer
Identification No.)
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
 Name of each exchange on which registered
Common Stock, $0.01 par value MYGN Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 Results of Operations and Financial Condition

On January 11, 2022, Paul J. Diaz, President and Chief Executive Officer of Myriad Genetics, Inc. (the “Company”), presented at the 40th Annual J.P. Morgan Health Care Conference using the presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, which reports information with respect to the third quarter of 2021 and the end of 2021, including, among other items, that the Company expects to enter 2022 with approximately $400 million in cash on hand (cash, cash equivalents and marketable investment securities) and no debt.

The preliminary unaudited financial data for the year ended December 31, 2021 set forth above is derived from preliminary internal financial reports. The Company has not yet finalized its complete results of operations for the year ended December 31, 2021. The Company and its auditors may identify items that would require the Company to make adjustments, some of which could be material, to the preliminary unaudited financial data set forth above.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01    Financial Statements and Exhibits.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 11, 2022By:/s/ R. Bryan Riggsbee
R. Bryan Riggsbee
Chief Financial Officer

EX-99.1 2 myriadgeneticsinc_final.htm EX-99.1 myriadgeneticsinc_final
Illuminating the path to better health through genetic insights 40th Annual J.P. Morgan Health Care Conference January 11, 2022 Paul J. Diaz President and CEO Myriad Genetics

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 2 Forward looking statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual and transition reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. Market opportunity figures and growth rates used in this presentation are estimates based on Company and third-party industry research. NON-GAAP FINANCIAL MEASURES In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad’s corporate website at www.myriad.com. 11 January 2022

©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us. As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease. Who we are, what we do, and why it matters Our purpose-led Mission Our Vision Health. Illuminated. Illuminating the path to better health through genetic insights. 311 January 2022

©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com What’s my risk of breast cancer? How can I learn more about my baby's health during pregnancy? Why isn’t my antidepressant working? How can I beat this cancerous tumor? 3 million patients 2.1 million patients 1.7 million patients 150,000 patients Empowering patients with answers and insights for better health + + 411 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Three focused businesses primed for growth 5 Operating Results Products Market* Business Oncology Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs & treatments. Q3 ‘21 volume: 47,829 Q3 ‘21 revenue: $76.8M $4B U.S. Market Growing 8% * Based upon company and industry research Helping physicians understand how genetic alterations impact patient response to antidepressants and other drugs. Mental Health Q3 ‘21 volume: 72,110 Q3 ‘21 revenue: $24.1M $5B U.S. Market Growing 15% Women’s Health Serving women of all ancestries, assessing risk of cancer and offering prenatal testing solutions. Q3 ‘21 volume: 110,141 Q3 ‘21 revenue: $59.1M $4B U.S. Market Growing 10% New 11 January 2022 New

Transformation and growth strategy

©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Strategic priorities Innovation that improves clinical outcomes, ease of use, and access Enterprise capabilities to accelerate growth and scale to market opportunity Investing in tech-enabled commercial tools to drive engagement, improve revenue cycle management, reduce complexity and cost Focus on execution and delivery of consistent results Disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability 7 A trusted, differentiated partner with specialized expertise Developing and enhancing best-in-class products to support growth, improve patient and provider experience and reach more patients of all backgrounds 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Executing our transformation plan, on track to accelerate growth 2H CY20 CY21 CY22 8 Build culture of service excellence, prioritize innovation, reduce complexity and cost Reset the base ✓ Launched transformation plan ✓ Redefined brand and mission ✓ Developed new commercial model ✓ Eliminated all outstanding debt ✓ Recovered test volumes Elevate current portfolio to full potential ✓ Debuted new brand and marketing strategy ✓ Reinvested and restructured sales force ✓ Enhanced reimbursement and revenue cycle management ✓ Initiated steps to fulfill commitment to ESG, including diversity, equity and inclusion ✓ Launched new products and offerings - MyRiskTM with RiskScore® for all ancestries - GeneSight® Psychotropic - MyGeneHistoryTM 3.0 Accelerate growth ✓ Build commercial capabilities to support new products and offerings ✓ Launch new enterprise commercial model ✓ Further develop direct-to-consumer channels ✓ Launch unified ordering portal ✓ Roll out ‘Lab of the Future’ – new sequencing technologies ✓ New investments in tech, IS infrastructure ✓ Strategic partnerships and acquisitions 1 2 3 11 January 2022

Mental Health

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Addressing the U.S. mental health crisis and need for medication testing 10 Mark Verratti – President Q3 '21 revenue: $24.1M 1.7M+ people tested to date 7 clinical studies published Market Mental Health Business • GeneSight volumes growing in key provider segments, including primary care, nurse practitioners • 95% of providers order through online portal • 10-15% of business originates from digital marketing efforts • 30% of kits are home-based tests • Exploring new partnerships in neurology to develop tests for early detection and treatment of Alzheimer's Elevating GeneSight® to full potential Helping physicians understand how genetic alterations impact patient response to antidepressants and other drugs. $5B U.S. Market Growing 15% 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Commercial model driving lead generation, conversion in mental health 11 Inside Sales cultivates broader base of leads – frees sales force to serve high potential accounts Field Sales works high potential, high revenue clinical leads Customer Paid Ads Brand Awareness Sales Targeting Website Optimization Search Engine Optimization 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Key drivers • Virtual patient testing capabilities • Online ordering • GeneSight@Home • Text and email messaging • Comprehensive mental health test, including ADHD 12 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 3Q 20 4Q 20 1Q 21 2Q 21 3Q 21 Volume Commercial model continues to drive new users Growing at >20% CAGR 11 January 2022

Women’s Health

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Serving healthcare providers and the women who rely on them 14 Leading health and wellness with best-in- class genetic insights for women of all ancestries, assessing risk of cancer and offering prenatal testing solutions. Melissa Gonzales – President Q3 '21 revenue: $59.1M Working to launch a version of GeneSight® test for women with postpartum depression Market Women’s Health Business 5-year and lifetime breast cancer risk assessment Only 1 out of 3 patients undergo carrier screening and NIPS during a pregnancy Unmet need to simplify process Comprehensive assessment with a single blood draw Combination noninvasive prenatal screening + carrier screening 2021 Launch 2023 Launch • Only test of its kind for women of all ancestries • 56% of women qualify for medical management (vs. 10% with standard hereditary cancer test) $4B U.S. Market Growing 10% 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Key product enhancement – personalized breast cancer risk for all women 15 • Only Myriad provides genetically-informed breast cancer risk assessment as part of a comprehensive panel, with equity in care for all patients • Closing the gap between women who meet NCCN guidelines for MyRisk and do not have European ancestry with those who do 11 January 2022 New in 2021

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Combined prenatal test simplifies and advances prenatal patient care • Early insight into recessive disease status • Eliminates unnecessary amniocentesis • Increased sensitivity for all pregnancies • Single maternal (no paternal) blood draw 16 Simplified Workflow Current Future Basic NIPS Parental CS + + = Maternal cfDNA Maternal DNA Paternal DNA + Fetal recessive status Not easily available with existing screening modalities Power of Prequel + Deeper fetal insights Maternal cfDNA * Scheduled for launch in 2023. Diagnostic test like amniocentesis still recommended as follow-up confirmation for a positive result. FirstGene provides insight into recessive status of the fetus in a screening modality Advantages New - early 2023 11 January 2022 Power of Foresight +


©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Providing answers that guide cancer treatment decisions 18 Business Faith Zaslavsky – President Q3 ‘21 revenue: $76.8M Market Oncology Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs and treatments. • Combining strength in germline/hereditary cancer testing and companion diagnostics • Expanding across care continuum with suite of offerings in one convenient, differentiated experience that provides oncologists with the single service they want • Building market-leading companion diagnostics portfolio – extending beyond ovarian to breast, prostate, and pancreatic cancer • Plan to expand portfolio into Liquid Bx treatment and Liquid Bx MRD $4B U.S. Market Growing 8% New 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Molecular diagnostics across the continuum of cancer care 19 Precise Liquid Bx Precise Liquid Bx Therapeutic Selection Precise Liquid Bx MRD Working to expand portfolio into Liquid Bx therapy selection and Liquid Bx MRD Measurable Residual Disease Monitoring Recurrence Treatment Selection & Clinical Trials Surgical Decisions High Risk Screening Planned Product Expansion: New 11 January 2022 New

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com A differentiated, comprehensive solution for advanced precision oncology Helping providers determine the best treatment plan – clear, integrated, personalized • Partnering with Intermountain Healthcare and Illumina to become the only lab with combination of: - World-class germline testing (MyRisk™ / BRACAnalysis CDx®) - HRD “Gold Standard” (MyChoice® CDx) - Best-in-class Comprehensive Genetic Tumor Panel (Illumina’s TSO500 / Precise™ Tumor) • Helping patients understand cancer genetics and if it affects their family 20 + + New New Launching this quarter 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Rapidly growing ~ $100M CDx business positioned for market expansion 21 0 20 40 60 BRACAnalysis CDx MyChoice CDx CDx Revenue (Q3 trailing 4 quarters in $M) US/International Pharma (R&D) $48 $42 • Market leading expertise with BRACAnalysis CDx and novel, patented homologous DNA-repair deficiency (HRD) test, MyChoice CDx • MyChoice CDx recently approved by US, European and Japanese regulatory agencies to predict response to PARP-inhibitors (PARPi’s) in ovarian cancer • Expanding MyChoice CDx into indications beyond ovarian cancers: - Currently being tested in more than a dozen clinical trials, including patients with breast, prostate, pancreatic and other cancer types - Approval to use MyChoice CDx in breast, prostate and pancreatic cancer represents an opportunity to expand MyChoice market by ~8X Total addressable market opportunity Companion diagnostics Ovarian Cancer $300M / year Breast, Prostate, Pancreatic Cancers $2B / year 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Simplifying treatment decisions for men with prostate cancer 2211 January 2022 Key Growth Drivers • ~250K men diagnosed with prostate cancer / year, 2nd most common cancer • $900M total addressable market – only 25% penetrated • Medicare and commercial coverage expanded to ALL risk patients with localized prostate cancer • Myriad is the only lab offering both germline testing (MyRisk, BRACAnalysis CDx) + biomarker analysis of tumor (Prolaris) 25% Test volume growth in Q3 2021 YOY 2X Revenue growth in Q3 2021, from ~$6.4M to ~$12.9M Operating Results Market leading tumor mRNA expression test that directly measures tumor cell growth -- helps identify how prostate cancer is behaving and what treatment options will be most effective in fighting it.

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Roadmap to expanding Myriad’s oncology portfolio 23 Launch Precise LBx Therapy Selection Launch Precise MRD Launch MyChoice CDx for multiple cancer types Launching Precise Oncology Solutions & Precise Tumor 2022 2023 2024 - 2025 Total $9B - $25B Incremental Annual Market Opportunity $1B $2B - $3B $1B $5B - $20B Advancing partnership negotiations to enter liquid market Partnership on LBx, existing whole exome and AmplifyTM technologies will enable and differentiate Myriad’s MRD offering Proven technology, on-going clinical trials and expansion of pharma partner relationships Combine commercial strength, clinical core and collaborations 11 January 2022

Accelerating new commercial capabilities

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Scaling our enterprise commercial and tech capabilities 25 High potential, innovative products Product/channel management Brand management and marketing Competitive intelligence and market planning Sales operations and performance management Tech-enabled customer experience 800 sales, medical, and customer service team members 60,000+ active ordering clinicians $50M+ tech investment to drive volume and improve customer engagement 95% of payers cover Myriad testing in network Commercial platform Oncology Women’s Health Mental Health $12M+ enterprise commercial and marketing capabilities 600+ EMR integrations and new unified ordering portal 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Investing in direct-to-consumer demand generation – promising early results 26 3-year goal >1 million qualified consumer leads for multiple products through patient-initiated testing Encounter Consider Inquire Tests Order reviewed and placed by healthcare provider Initiates genetic testing Visits website to see if testing is appropriate for them Sees targeted ads Q3 '21 results: Qualified lead conversion up > 28% and growing through telemedicine + direct kit shipment 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Customized end-to-end solutions for easy customer experience Myriad Complete™ Suite of services and workflow solutions • Simplifies genetic testing through patient and provider support at every step • Seamlessly integrates into clinic workflow • Saves time and streamlines workflow • Customizable based on clinic needs 27 Patient Identification based on medical society guidelines • Digital screening with MyGeneHistoryTM • Radiology information systems • Mammography info systems Ordering • Online portal • Virtual orders • EMR Integrations • Phlebotomy Results with MyRiskTM Management Tool • Personalized Risk assessment • Online portal • EMR integration Pre-test Education with Certified Genetic Counselor • Individualized education • Follow-up documentation Affordability • Personalized cost estimates • In-network with 95% of payors • Financial assistance for those who qualify Post-test consults with certified Genetic Counselor • Individualized discussion of results • Detailed summary notes 1 3 5 2 4 6 11 January 2022

Stabilizing business and driving sustainable growth

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Myriad continues to stabilize business and improve operating and financial results Financial highlights • Restored same-store growth • Improved gross margins and profitability through disciplined expense controls • Returned $400M to balance sheet through divestitures and improved revenue cycle management • Expect to enter 2022 with ~$400M cash and no debt 29 Q3’21 YoY volume: +20% Q3’21 YoY revenue: +27% 55.8 56.3 55.2 67.3 59.1 58.3 60.4 75.6 76.3 76.8 11.9 18.0 17.6 22.6 24.1 - 50,000 100,000 150,000 200,000 250,000 300,000 0 20 40 60 80 100 120 140 160 180 Q3-20 Q4-20 Q1-21 Q2-21 Q3-21 T e s t V o lu m e R e v e n u e ( $ m il li o n s ) WH Onc MH Volume *excludes divested assets 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com MyRisk stabilization Expect organic revenue growth to accelerate in 2022 going into 2023 through improved sales and marketing execution, product and technology innovation 30 +4-5% +3-4% +2-3% Accelerating growth rate in ’24+9-12% Mental Health GeneSight® momentum Women’s Health FirstGeneTM -- Combined Prequel and Foresight product launch Expanded medical association guidelines Oncology PreciseTM oncology solution launch MyChoiceTM CDx expansion Prolaris® momentum Upside New oncology solutions including liquid biopsy and MRD Women’s Health product and channel expansion Companion diagnostics expansion of indications and pharma partnerships M&A / strategic partnerships 1 2 3 4 5 RiskScore for all ancestries Streamlined ordering and billing services, EMR integration Direct-to-consumer channel estimated organic revenue growth ‘22-’24 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Myriad Genetics 2022 financial guidance 31 Guidance Key Assumptions Revenue* $670-$700 8% - 13% growth from 2021 baseline that excludes divested assets and positive cash collections from prior period orders Gross Margin % 70% - 72% Gross margins impacted by benefits from lab efficiencies and automations offset by increasing supply costs & wage inflation Adjusted Operating Expenses* $470 - $480 Operating expenses impacted by investments in technology, commercial tools, R&D as well as inflationary pressures Adjusted EPS $0.00 - $0.20 *In millions 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Significant market growth in focused business areas Best-in-class product quality Strong scalable commercial engine Size/scale within the industry Tech, data and research capabilities Industry leading operating margins & profitability Investment considerations: Myriad strengths and strategic advantages Leader in genetic testing and precision medicine • Transformation and growth strategy on track • Broad and growing commercial capabilities with 60K healthcare providers ordering Myriad products across Women’s Health, Oncology and Mental Health • Commercial platform with market-leading breadth of payer relationships and revenue cycle management capabilities • Trusted, differentiated healthcare partner with specialized expertise 3211 January 2022


Appendix – Third quarter 2021 operating and financial results

©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Third quarter operating and financial results were strong, despite COVID-19 headwinds and typical seasonal softness Total revenue of $167.3M increased 15% YOY Excluding the impact of the divested Vectra, RBM and myPath businesses, quarterly revenue increased 27% YOY Diagnostic test volumes of 252,000 increased 15% YOY. Stability in ASPs for past four quarters, excluding impact of out-of-period collections GAAP total operating expenses were $199.4 million; adjusted total operating expenses decreased $1.6 million sequentially to $121.5 million GAAP EPS of $0.30; Adjusted EPS were ($0.02), and we remain on track to return to profitability in 2022 35 GAAP operating loss in the quarter was ($79.9) million; adjusted operating loss was ($1.4) million 1 2 3 4 5 Closed divestiture of Myriad Autoimmune (Vectra) business Paid down revolving credit facility - $413.6 million cash, cash equivalents and investments 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Consolidated quarterly highlights Revenue, adjusted gross margin, adjusted operating income, adjusted EPS Quarter ended 36 In millions September 2021 June 2021 September 2020 Revenue $167.3 $189.4 $145.2 Sequential change (12%) 9% — Adjusted gross margin 71.7% 72.1% 69.8% Sequential change -40 bp +70 bp — Adjusted op income (loss) ($1.4) $13.5 ($12.3) Sequential change ($14.9) +$16.8 — Adjusted op income (loss) ($0.02) $0.12 ($0.15) Sequential change ($0.14) +$0.18 — Revenue from prior period collections $8 $13 ($2) 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Third quarter 2021 — revenue by product Three months ended September 30 37 2021 2020 In millions Women’s Health Oncology Mental Health Other Total Women’s Health Oncology Mental Health Other Total % Change Hereditary cancer $35.5 $43.9 — — $79.4 $39.2 $41.3 — — $80.5 (1%) Tumor profiling — 32.9 — — 32.9 — 17.0 — — 17.0 94% Prenatal 23.6 — — — 23.6 16.6 — — — 16.6 42% Pharmacogenomics — — 24.1 — 24.1 — — 11.9 — 11.9 103% Autoimmune — — — 7.3 7.3 — — — 9.1 9.1 (20%) Other — — — — — — — — 0.6 0.6 (100%) Total molecular diagnostic revenue 59.1 76.8 24.1 7.3 167.3 55.8 58.3 11.9 9.7 135.7 23% Pharmaceutical and clinical service revenue — — — — — — — — 9.5 9.5 (100%) Total revenue $59.1 $76.8 $24.1 $7.3 $167.3 $55.8 $58.3 $11.9 $19.2 $145.2 15% 11 January 2022

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Revenue and test performance Year-over-year change September 2020-September 2021 38 Revenue Test Volume Hereditary cancer (1%) 0% Prenatal 42% 7% Tumor profiling 94% 33% Pharmacogenomics 103% 71% Overall company 15% 15% Overall company (excluding divestitures) 27% 20% ASP Stable 11 January 2022

EX-101.SCH 3 mygn-20220111.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mygn-20220111_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Written Communications Written Communications City Area Code City Area Code Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Title of 12(g) Security Title of 12(g) Security Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 5 mygn-20220111_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 myriadgeneticsinc_final001.jpg GRAPHIC begin 644 myriadgeneticsinc_final001.jpg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